SGT-003
SGT-003 is an experimental gene therapy being tested for Duchenne's muscular dystrophy.[1][2][3] It is hoped to be an improvement on Solid Bioscience's earlier gene therapy SGT-001.[4]
References[edit]
- ^ Bizot, Flavien (20 March 2023). "Optimization of exon skipping therapy for the treatment of Duchenne muscular dystrophy". Université Paris-Saclay.
{{cite journal}}: Cite journal requires|journal=(help) - ^ Roberts, Thomas C.; Wood, Matthew J. A.; Davies, Kay E. (November 2023). "Therapeutic approaches for Duchenne muscular dystrophy". Nature Reviews Drug Discovery. 22 (11): 917–934. doi:10.1038/s41573-023-00775-6. ISSN 1474-1784. PMID 37652974. S2CID 261429544.
- ^ "Solid Biosciences (SLDB) Stock Up as FDA Clears DMD Drug IND". Yahoo Finance. 16 November 2023. Retrieved 19 November 2023.
- ^ "3-Year Outcomes Update in the IGNITE DMD Phase 1/2 Study of SGT-001 Microdystrophin Gene Therapy". MDA Clinical & Scientific Conference 2023. Retrieved 19 November 2023.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |